Cited by 477HER2/EGFR in Cancer ResearchLung Cancer Treatments and MutationsGastric Cancer Management and Outcomes

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells

Shattuck, David L., Miller, Jamie K., Carraway, Kermit L., Sweeney, Colleen·2008·Cancer Research

Open this paper in CoChat — free account

Abstract

Her2 is overexpressed in 20% to 30% of breast tumors and correlates with reduced disease-free and overall patient survival. Trastuzumab, a humanized monoclonal antibody directed against Her2, represents the first Her2-targeted therapy, which decreases the risk of relapse and prolongs patient survival. Resistance to trastuzumab, both inherent and treatment-acquired, represents a significant barrier to the effective treatment of Her2 (+) breast cancer. The Met receptor tyrosine kinase is aberrantly expressed in breast cancer and predicts poor patient prognosis. In this study, we find that Met is frequently expressed in Her2-overexpressing breast cancer cells, as well as Her2 (+) breast cancer. Importantly, Met contributes to trastuzumab resistance, as inhibition of Met sensitizes cells to trastuzumab-mediated growth inhibition, whereas Met activation protects cells against trastuzumab by abrogating p27 induction. Remarkably, Her2-overexpressing breast cancer cells rapidly up-regulate Met expression after trastuzumab treatment, promoting their own resistance. Our study suggests that a subset of Her2 (+) patients may benefit from combined inhibition of Her2 and Met.

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-07-5962

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., et al. (2007) · Science · doi:10.1126/science.1141478 · Cited by 4,496
Model-based analysis of oligonucleotide arrays: Expression index computation and outlier detection.
Li, C., & Wong, W. H. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.98.1.31 · Cited by 3,133
Trastuzumab — Mechanism of Action and Use in Clinical Practice
Hudis, C. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmra043186 · Cited by 2,640
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients
Nagata, Y., Lan, K.-H., Zhou, X., Tan, M., Esteva, F. J., Sahin, A. A., Klos, K. S., Li, P., Monia, B. P., Nguyen, N. T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.022 · Cited by 1,858
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer
Berns, K., Horlings, H. M., Hennessy, B. T., Madiredjo, M., Hijmans, E. M., Beelen, K., Linn, S. C., Gonzalez-Angulo, A. M., Stemke-Hale, K., Hauptmann, M., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.030 · Cited by 1,627
Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)
Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D. D., & Pollak, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1852 · Cited by 886
Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells
Nahta, R., Yuan, L. X. H., Zhang, B., Kobayashi, R., & Esteva, F. J. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3841 · Cited by 793
Mechanisms of Disease: oncogene addiction—a rationale for molecular targeting in cancer therapy
Weinstein, I. B., & Joe, A. K. (2006) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0558 · Cited by 739
Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer
Valabrega, G., Montemurro, F., & Aglietta, M. (2007) · Annals of Oncology · doi:10.1093/annonc/mdl475 · Cited by 636
Human Breast Cancer Cells Selected for Resistance to Trastuzumab In vivo Overexpress Epidermal Growth Factor Receptor and ErbB Ligands and Remain Dependent on the ErbB Receptor Network
Ritter, C. A., Perez-Torres, M., Rinehart, C., Guix, M., Dugger, T., Engelman, J. A., & Arteaga, C. L. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0701 · Cited by 497

Show all 43 references

Sorted by citations

Items 401–477 of 477

Suppression of mammary tumorigenesis by a Gemini vitamin D analog and a synthetic truterpenoid
So, J. Y. (2013) · doi:10.7282/t3jw8ck7
Angiotensin-(1-7): A Peptide Hormone Inhibitor for the Treatment of Breast Cancer Targeting the Tumor Microenvironment
Cook, K. L. (2010) · WakeSpace Scholarship (Wake Forest University)
Reviewmechanisms of acquired resistance to tyrosine kinase targeted therapy
Sierra, J. R., Cepero, V., & Giordano, S. (2010)
Targeting HER2+ and trastuzumab-resistant metastatic breast cancer
Cortés, J., & Scaltriti, M. (2011) · CRC Press eBooks · doi:10.3109/9781841848129-6
Use of genetically engineered mouse models in preclinical drug development
Creedon, H. (2015) · ERA
The receptor tyrosine kinase Met and the protein tyrosine phosphatase PTPN2 in breast cancer
Veenstra, C. (2017) · Linköping University medical dissertations · doi:10.3384/diss.diva-135047
A novel function for 12-lipoxygenase in c-Met and integrin beta4 axis crosstalk
Tovar, E. A. (2014)
Targeted Therapy in Advanced Gastric Cancer: An Updated Review Keywords: Gastric cancer; Gastric adenocarcinoma; Targeted
Shum, H., & Rajdev, L. N. (2014)
Targeting the Triple-Negative Breast Cancer Kinome with Chemical Proteomics
Whittle, M. C. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/p21s-v784
Epigenetic regulation of resistance to treatments in triple negative and HER2+ breast cancer: miRNAs involved
Navarro, P. C. (2020) · doi:10.4995/thesis/10251/153807
Mecanismos de resistencia al trastuzumab
Korbenfeld, E. P. (2012) · Oncología Clínica · doi:10.56969/oc.v17i1.130
Targeting the EGFR family of receptor tyrosine kinases
Zhang, S., & Yu, D. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9781139046947.080
Faculty Opinions recommendation of Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways.
Toker, A., & White, C. D. (2011) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.10060956.11471056
Significance of Tumor Heterogeneity of p-Smad2 and c-Met in HER2-positive Gastric Carcinoma with Lymph Node MetastasisPreprint
Tsujio, G., Maruo, K., Yamamoto, Y., Sera, T., Sugimoto, A., Kasashima, H., Miki, Y., Yoshii, M., Tamura, T., Toyokawa, T., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1464094/v1
Targeting HER2+and trastuzumab-resistant metastatic breast cancer
Cortés, J., & Scaltriti, M. (2011) · Informa Healthcare eBooks · doi:10.3109/9781841848129.004
Targeted Therapy in Advanced Gastric Cancer: An Updated Review
Shum, H., & Rajdev, L. N. (2014) · Journal of Cancer Sciences · doi:10.13188/2377-9292.1000003
Pertuzumab (Perjeta®)
Garca‐Saénz, J. A., Antón, F. M., & Bueno, C. (2014) · doi:10.1002/9783527682423.ch67
Emerging targeted agents for HER2-positive breast cancer
Zardavas, D., & Piccart, M. J. (2016) · Springer eBooks · doi:10.1007/978-3-319-28216-9_6
Bioactive Compounds from Marine-Derived Aspergillus, Penicillium, Talaromyces and Trichoderma Species
Nicoletti, R., & Vinale, F. (2019) · MDPI eBooks · doi:10.3390/books978-3-03897-981-4
Olea europaea L.
Kırcı, D., & Ayaz, F. (2022) · Springer eBooks · doi:10.1007/978-3-031-07753-1_30
Use of MET kinase inhibitors to overcome cetuximab resistance in colorectal cancer
Ma, Z., Fu, W., Lei, C., & Hu, S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-821584-5.00019-5
Data from β1-Integrin Circumvents the Antiproliferative Effects of Trastuzumab in Human Epidermal Growth Factor Receptor-2–Positive Breast Cancer
Lesniak, D. M., Xu, Y., Deschênes, J., Lai, R. L., Thoms, J., Murray, D., Gosh, S., Mackey, J. R., Sabri, S., & Abdulkarim, B. (2023) · doi:10.1158/0008-5472.c.6500066.v1
Data from The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient–Derived Xenograft Models
Schuller, A. G., Barry, E., Jones, R. D. O., Henry, R. E., Frigault, M. M., Beran, G. J., Linsenmayer, D. C., Hattersley, M. M., Smith, A., Wilson, J., et al. (2023) · doi:10.1158/1078-0432.c.6524580
Data from Silencing Kinase-Interacting Stathmin Gene Enhances Erlotinib Sensitivity by Inhibiting Ser10 p27 Phosphorylation in Epidermal Growth Factor Receptor–Expressing Breast Cancer
Zhang, D., Tari, A. M., Akar, U., Arun, B., LaFortune, T. A., Nieves-Alicea, R., Hortobágyi, G. N., & Ueno, N. T. (2023) · doi:10.1158/1535-7163.c.6531732.v1
Target Hyperactive ERK Signaling for Cancer Therapy
Yap, J., & Hu, J. (2023) · Springer eBooks · doi:10.1007/978-3-030-80962-1_257-1
MET functions in tumour progression and therapy resistance are repressed by intronic polyadenylationPreprint
Boldina, G., Vallejos, M., Allard, D., Cadix, M., Labbé, C. M., Vacher, S., Hemmingsson, O., Gestraud, P., Teissandier, A., Martineau, S., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.09.552237
In silico Approaches to Tyrosine Kinase Inhibitors’ Development
Sugunakala, S., & Selvaraj, S. (2023) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815136807123010014
Additional file 2 of ERα-related chromothripsis enhances concordant gene transcription on chromosome 17q11.1-q24.1 in luminal breast cancer
Lin, C.-L., Tan, X., Chen, M., Kusi, M., Hung, C., Chou, C., Hsu, Y., Wang, C., Kirma, N. B., Chen, C., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12308207
Biosimilars in Breast Cancer
Bhatt, D. (2024) · Springer eBooks · doi:10.1007/978-981-97-3001-8_10
Biological mechanisms of resistance to trastuzumab and ways to overcome them: Mod-ern problems of clinical oncology
Vynnychenko, О. І., & Moskalenko, R. (2024) · Regulatory Mechanisms in Biosystems · doi:10.15421/022449
Receptor Tyrosine Kinase Inhibitors in Combination Therapies: Integrating Chemotherapy and Radiation Therapy for Improved Cancer Treatment
Patel, R. P., & Varghese, J. F. (2025) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-031-93894-8_9
Macrophage-Related Interaction Pathways in Tumor Stroma
Gusenbauer, S. (2012) · mediaTUM – the media and publications repository of the Technical University Munich (Technical University Munich)
Additional file 1 of ERα-related chromothripsis enhances concordant gene transcription on chromosome 17q11.1-q24.1 in luminal breast cancer
Lin, C.-L., Tan, X., Chen, M., Kusi, M., Hung, C.-N., Chou, C.-W., Hsu, Y.-T., Wang, C.-M., Kirma, N. B., Chen, C.-L., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12308198
Additional file 6 of Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell lines
Ebert, K., Zwingenberger, G., Barbaria, E., Keller, S., Heck, C., Arnold, R., Hollerieth, V., Mattes, J., Geffers, R., Raimúndez, E., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13161084
Additional file 5 of Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell lines
Ebert, K., Zwingenberger, G., Barbaria, E., Keller, S., Heck, C., Arnold, R., Hollerieth, V., Mattes, J., Geffers, R., Raimúndez, E., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13161081
Additional file 2 of A receptor-antibody hybrid hampering MET-driven metastatic spread
Modica, C., Basilico, C., Chiriaco, C., Borrelli, N., Comoglio, P. M., & Vigna, E. (2021) · Figshare · doi:10.6084/m9.figshare.13578801
Additional file 1 of A receptor-antibody hybrid hampering MET-driven metastatic spread
Modica, C., Basilico, C., Chiriaco, C., Borrelli, N., Comoglio, P. M., & Vigna, E. (2021) · Figshare · doi:10.6084/m9.figshare.13578798
Additional file 7 of Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth
Keller, M., Rohlf, K., Glotzbach, A., Leonhardt, G., Lüke, S., Derksen, K., Demirci, Ö., Göçener, D., Alwahsh, M., Lambert, J., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22609828
Additional file 4 of Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell lines
Ebert, K., Zwingenberger, G., Barbaria, E., Keller, S., Heck, C., Arnold, R., Hollerieth, V., Mattes, J., Geffers, R., Raimúndez, E., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13161078
Additional file 4 of Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth
Keller, M., Rohlf, K., Glotzbach, A., Leonhardt, G., Lüke, S., Derksen, K., Demirci, Ö., Göçener, D., Alwahsh, M., Lambert, J., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22609819
Additional file 6 of A receptor-antibody hybrid hampering MET-driven metastatic spread
Modica, C., Basilico, C., Chiriaco, C., Borrelli, N., Comoglio, P. M., & Vigna, E. (2021) · Figshare · doi:10.6084/m9.figshare.13578813
Additional file 3 of Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell lines
Ebert, K., Zwingenberger, G., Barbaria, E., Keller, S., Heck, C., Arnold, R., Hollerieth, V., Mattes, J., Geffers, R., Raimúndez, E., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13161075
Additional file 3 of Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth
Keller, M., Rohlf, K., Glotzbach, A., Leonhardt, G., Lüke, S., Derksen, K., Demirci, Ö., Göçener, D., Alwahsh, M., Lambert, J., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22609816
Additional file 5 of Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth
Keller, M., Rohlf, K., Glotzbach, A., Leonhardt, G., Lüke, S., Derksen, K., Demirci, Ö., Göçener, D., Alwahsh, M., Lambert, J., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22609822
Additional file 5 of A receptor-antibody hybrid hampering MET-driven metastatic spread
Modica, C., Basilico, C., Chiriaco, C., Borrelli, N., Comoglio, P. M., & Vigna, E. (2021) · Figshare · doi:10.6084/m9.figshare.13578810
Additional file 2 of Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial
Song, Z., Li, Y., Chen, S., Ying, S., Xu, S., Huang, J., Wu, D., Lv, D., Bei, T., Liu, S., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19101740
Additional file 6 of Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth
Keller, M., Rohlf, K., Glotzbach, A., Leonhardt, G., Lüke, S., Derksen, K., Demirci, Ö., Göçener, D., Alwahsh, M., Lambert, J., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22609825
Additional file 8 of Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth
Keller, M., Rohlf, K., Glotzbach, A., Leonhardt, G., Lüke, S., Derksen, K., Demirci, Ö., Göçener, D., Alwahsh, M., Lambert, J., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22609831
Additional file 2 of Significance of tumor heterogeneity of p-Smad2 and c-Met in HER2-positive gastric carcinoma with lymph node metastasis
Tsujio, G., Maruo, K., Yamamoto, Y., Sera, T., Sugimoto, A., Kasashima, H., Miki, Y., Yoshii, M., Tamura, T., Toyokawa, T., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19959996
Additional file 2 of Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth
Keller, M., Rohlf, K., Glotzbach, A., Leonhardt, G., Lüke, S., Derksen, K., Demirci, Ö., Göçener, D., Alwahsh, M., Lambert, J., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22609813
Additional file 3 of A receptor-antibody hybrid hampering MET-driven metastatic spread
Modica, C., Basilico, C., Chiriaco, C., Borrelli, N., Comoglio, P. M., & Vigna, E. (2021) · Figshare · doi:10.6084/m9.figshare.13578804
Additional file 1 of Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell lines
Ebert, K., Zwingenberger, G., Barbaria, E., Keller, S., Heck, C., Arnold, R., Hollerieth, V., Mattes, J., Geffers, R., Raimúndez, E., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13161069
Additional file 1 of SH3BGRL confers innate drug resistance in breast cancer by stabilizing HER2 activation on cell membrane
Li, H., Zhang, M., Wei, Y., Haider, F., Lin, Y., Guan, W., Liu, Y., Zhang, S., Yuan, R., Yang, X., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12269921
Additional file 7 of A receptor-antibody hybrid hampering MET-driven metastatic spread
Modica, C., Basilico, C., Chiriaco, C., Borrelli, N., Comoglio, P. M., & Vigna, E. (2021) · Figshare · doi:10.6084/m9.figshare.13578816
Additional file 1 of Significance of tumor heterogeneity of p-Smad2 and c-Met in HER2-positive gastric carcinoma with lymph node metastasis
Tsujio, G., Maruo, K., Yamamoto, Y., Sera, T., Sugimoto, A., Kasashima, H., Miki, Y., Yoshii, M., Tamura, T., Toyokawa, T., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19959993
Additional file 1 of Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth
Keller, M., Rohlf, K., Glotzbach, A., Leonhardt, G., Lüke, S., Derksen, K., Demirci, Ö., Göçener, D., Alwahsh, M., Lambert, J., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22609810
Additional file 4 of A receptor-antibody hybrid hampering MET-driven metastatic spread
Modica, C., Basilico, C., Chiriaco, C., Borrelli, N., Comoglio, P. M., & Vigna, E. (2021) · Figshare · doi:10.6084/m9.figshare.13578807
Additional file 2 of Determining the effects of trastuzumab, cetuximab and afatinib by phosphoprotein, gene expression and phenotypic analysis in gastric cancer cell lines
Ebert, K., Zwingenberger, G., Barbaria, E., Keller, S., Heck, C., Arnold, R., Hollerieth, V., Mattes, J., Geffers, R., Raimúndez, E., et al. (2020) · Figshare · doi:10.6084/m9.figshare.13161072
Additional file 1 of Efficacy and safety of pyrotinib in advanced lung adenocarcinoma with HER2 mutations: a multicenter, single-arm, phase II trial
Song, Z., Li, Y., Chen, S., Ying, S., Xu, S., Huang, J., Wu, D., Lv, D., Bei, T., Liu, S., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19101737
Target Hyperactive ERK Signaling for Cancer Therapy
Yap, J., & Hu, J. (2025) · Springer eBooks · doi:10.1007/978-3-032-00771-1_257
Photoactivatable DNA Conveyer Ferries Cellular Receptors to Lysosome for Collaborative Degradation in Zebrafish
Chen, S., Zhuo, Y., Pang, L., Liang, H., Lin, X., & Li, J. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c20326
Unraveling the potential of USP8 as a therapeutic target for overcoming c-Met-mediated resistance in breast cancer: A review
Amuji, D. N., Zakari, S., Pirisola, A. J., Ogunlana, O. O., & Iweala, E. E. J. (2025) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2025.101089
Dégradation du récepteur tyrosine kinase Met par clivages protéolytiques
Ancot, F. (2010) · doi:10.70675/6b0027cazed89z4ad3z9031z61ca93fe127b
Effet de l’expression de la GD3 synthétase sur la progression et l’agressivité du cancer du sein
Cazet, A. (2010) · doi:10.70675/db7f2cc7zc960z4010z9c7bzbc4b5ba2c685
Régulation de l'invasion cellulaire induite par les tyrosine kinases dans le cancer du sein
Chevalier, C. (2014) · theses.fr (ABES) · doi:10.70675/692c8de1za82az4e5ez953bz5e90670eb75d
Développement d'anticorps bispécifiques de lama pour le traitement de cancers du sein réfractaires à l'action du trastuzumab
Turini, M. (2014) · theses.fr (ABES) · doi:10.70675/45aafa15z8f24z47c4z8939z841cffb8808f
Contrôle de la progression tumorale broncho-pulmonaire par FHIT : Implication du récepteur HER2
Jouida, A. (2017) · theses.fr (ABES) · doi:10.70675/d7d69aafzfaebz4f24z855dz70ea0b9a846e
Conséquences de la dérégulation de MET sur le phénotype des cancers bronchiques non à petites cellules EGFR mutés devenus résistant aux inhibiteurs de tyrosine kinase d’EGFR
Baldacci, S. (2017) · doi:10.70675/ea435494z4946z4d12za5f5zd338f77b537b
Modelling heterogeneity of triple-negative breast cancer in mice to uncover and target signaling essentiality
Ahmad, F. (2020) · doi:10.70675/38ea7a7bz655dz40d1z8ef9z6474106f8e19
ctDNA-guided precision therapy with trastuzumab deruxtecan plus pyrotinib in HER2-positive breast cancer brain metastases: a case report
Zhou, D., Wu, Y., Guo, S., Li, P., Li, G., Yang, M., Wang, S., & Yang, F. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1826447
Molecular Mechanisms Underlying Recurrence in Triple-Positive Breast Cancer (ER+/PR+/HER2+) and Potential Repurposing of Multi-Target Inhibitors
Bandala, C., López-Méndez, J. A., Díaz-Rivera, M. R. J., Carro-Rodríguez, J., & Bello, M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27125440
HER2 targeted therapy resistance in breast cancer: from molecular landscape to clinical aspects
Zhang, H., Ma, D., Li, F., Shao, Z., & Chen, C. (2026) · Science China Life Sciences · doi:10.1007/s11427-025-3311-5
BindingDB Entry 50047556: Synthesis, antitumor evaluation and molecular docking studies of [1,2,4]triazolo[4,3-b][1,2,4,5]tetrazine derivatives.
BindingDB (2017) · UC San Diego · doi:10.7270/q2t155jj
BindingDB Entry 50039987: 'Click' synthesis of a triazole-based inhibitor of Met functions in cancer cells.
BindingDB (2013) · UC San Diego · doi:10.7270/q2pv6mf0
BindingDB Entry 50034285: Identification of new aminoacid amides containing the imidazo[2,1-b]benzothiazol-2-ylphenyl moiety as inhibitors of tumorigenesis by oncogenic Met signaling.
BindingDB (2012) · UC San Diego · doi:10.7270/q2xk8fzt
Novel Role of ErbB-2 in Inhibition of Jagged-1-Mediated Trans-Activation of Notch in Breast Cancer
Pandya, K. (2013) · Loyola eCommons (Loyola University of Chicago)
Discerning the role of Kruppel-like factor 4 in breast cancer
Yori, J. L. (2011) · OhioLink ETD Center (Ohio Library and Information Network)

Authors: Shattuck, D. L., Miller, J. K., Carraway, K. L., & Sweeney, C.
Affiliations: UC Davis Comprehensive Cancer Center (US)
ORCID: Carraway, Kermit L.
Sweeney, Colleen
Venue: Cancer Research
Publisher: American Association for Cancer Research (AACR)
Published: 2008-03-01
Volume: 68
Issue: 5
Pages: 1471-1477
ISSN: 0008-5472 (ISSN-L)
1538-7445
DOI: 10.1158/0008-5472.can-07-5962
OpenAlex: W2027684043
Cited by: 473
References: 43
Citations by year: 2026: 6 · 2025: 18 · 2024: 12 · 2023: 30 · 2022: 18 · 2021: 22 · 2020: 34 · 2019: 24 · 2018: 22 · 2017: 24 · 2016: 26 · 2015: 33 · 2014: 37 · 2013: 41 · 2012: 42
FWCI: 14.78
Type: journal article
Language: en
Open access: closed
Locations: Cancer Research (publishedVersion)
PubMed (publishedVersion)
Funders: National Cancer Institute (CA123541, R01CA118384, R01CA123541, CA118384)
Topics: Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Oncology › Gastric Cancer Management and Outcomes
Keywords: MET receptor tyrosine kinase, trastuzumab resistance, HER2-positive breast cancer, combination therapy, MET inhibition, HER2-targeted therapy, drug resistance
MeSH terms: Trastuzumab, Antibodies, Monoclonal, Antineoplastic Agents, Breast, Breast Neoplasms, Humans, Models, Biological, Phosphorylation, Gene Expression Regulation, Neoplastic, Erb-b2 Receptor Tyrosine Kinases, Genes, erbB-2, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-met, Cell Line, Tumor, Extracellular Signal-Regulated MAP Kinases, Cell Proliferation, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Met Receptor Contributes to Trastuzumab Resistance of Her2-Overexpressing Breast Cancer Cells

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks